Al­ny­lam CEO de­fends changes to cru­cial AT­TR tri­al: 'We re­al­ly are play­ing to win'

NEW YORK — Al­ny­lam’s sur­prise change to the analy­sis plan for one of this year’s most an­tic­i­pat­ed clin­i­cal tri­al read­outs set off a flur­ry of ques­tions around the fu­ture of the com­pa­ny’s AT­TR fran­chise and the out­look of its up­com­ing re­sults.

“It’s not based on some, ‘Oh my good­ness, we’ve seen some­thing, there­fore we need to change,” Al­ny­lam CEO Yvonne Green­street said in an in­ter­view with End­points News in New York. In­stead, the up­dates could help Al­ny­lam show a greater dif­fer­ence be­tween the ef­fects of its med­i­cine and place­bo, and re­flect a com­mer­cial mar­ket that may re­sist pay­ing for Al­ny­lam’s ther­a­py in com­bi­na­tion with Pfiz­er’s drug tafamidis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER